==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Browse result page of THPdb

The total number entries retrieved from this search are 7
IDThPPIDNamePeptide SequenceLengthFunctional ClassificationDiseaseBrandCompanyPhysical AppearanceRoute of AdministartionCategoryTarget
1423Th1071PancrelipasePancreatic alpha amy Full view1206IaMetabolic/genetic/ViokaceAptalis Pharma US, Inc.Beige-white amorphous powder, miscible in water and practically insoluble in alcohol and converted to tablet formOral routeGastrointestinal Agents and Enzyme Replacement Agents Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch
1648Th1148AliskirenN.A.
Full view
0IIaMetabolicTekturnaPhysicians Total Care, Inc.Light-pink, biconvex round tabletOral routeRenin inhibitor Renin
1649Th1148AliskirenN.A.
Full view
0IIaMetabolicTekturnaNovartis Pharmaceuticals CorporationLight-pink, biconvex round tabletOral routeRenin inhibitor Renin
1650Th1148AliskirenN.A.
Full view
0IIaMetabolicTekturna HCTNovartis Pharmaceuticals CorporationBiconvex, ovaloid film-coated tablets.Oral routeRenin inhibitor Renin
1651Th1148AliskirenN.A.
Full view
0IIaMetabolicTekamloNovartis Pharmaceuticals CorporationTablets (aliskiren/amlodipine): 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg, 300 mg/10 mgOral routeRenin inhibitor Renin
1652Th1148AliskirenN.A.
Full view
0IIaMetabolicAmturnideNovartis Pharmaceuticals CorporationTablets (aliskiren/ amlodipine/ HCTZ): 150/5/12.5, 300/5/12.5, 300/5/25, 300/10/12.5, 300/10/25 mg. Oral routeRenin inhibitor Renin
1653Th1149Ragweed Pollen ExtractN.A.
Full view
0IIIaImmunologicalRagwitekMerck Sharp & DohmeTabletsOral routeN.A. N.A.